How Much Did VitroLabs Raise?
Funding & Key Investors

VitroLabs has successfully secured a major strategic investment, marking a pivotal milestone in its mission to revolutionize the luxury materials market. With a cumulative capital infusion reaching $53.2M, the company is well-positioned to accelerate its proprietary tissue engineering platform. This latest injection of $53M underscores investor confidence in the firm's ability to bridge the gap between laboratory-scale innovation and industrial-grade production of cell-cultivated leather.

What is VitroLabs?

VitroLabs
Business ServicesResearch & DevelopmentManufacturing

Founded in 2016 and headquartered in Milpitas, California, VitroLabs operates at the intersection of biotechnology and sustainable fashion. The company has developed a sophisticated platform that utilizes a one-time collection of animal cells to grow durable, high-performance leather in a controlled, nutrient-rich environment. By bypassing traditional livestock farming, VitroLabs addresses critical environmental and ethical concerns while maintaining the aesthetic and tactile complexity of conventional hides. This technological breakthrough allows for the production of luxury-grade materials that meet the rigorous standards of the fashion industry without the ecological footprint associated with traditional leather manufacturing.

How much funding has VitroLabs raised?

VitroLabs has raised a total of $53.1M across 2 funding rounds:

2020

Debt

$150K

2022

Series A

$53M

Debt (2020): $150K with participation from PPP

Series A (2022): $53M led by FWD, Kering, and Agronomics

Key Investors in VitroLabs

FWD

A strategic investment group focused on supporting disruptive technologies that drive long-term industrial transformation.

Kering

A global luxury group managing a portfolio of renowned houses, with a strong emphasis on sustainability and innovation in fashion materials.

Agronomics

A leading venture capital firm specializing in the cellular agriculture sector, providing capital to companies developing sustainable food and material alternatives.

What's next for VitroLabs?

Following this major enterprise-level funding, VitroLabs is poised to transition into a phase of rapid commercial scaling. The strategic focus will likely shift toward optimizing production efficiency and expanding manufacturing capacity to meet the growing demand for sustainable, high-quality alternatives in the global luxury sector. By leveraging its recent capital, the company aims to solidify its supply chain partnerships and refine its tissue engineering processes, ensuring that its cultivated leather becomes a viable, scalable standard for premium brands seeking to reduce their environmental impact while upholding product excellence.

See full VitroLabs company page
See More Financial Insights
No matching results.
Refine your search.

Additional financial insights in the Business Services industry

Accounting for Legal PracticesBusiness ServicesProject Management
Business ServicesProject Management
Advertising NetworksBusiness ServicesProject Management
Business ServicesHuman Resources Management Systems (HRMS)

Frequently Asked Questions Regarding VitroLabs Financial Insights

What are the most recent funding rounds that VitroLabs has completed, and what were the funding rounds?
VitroLabs has recently completed 2 funding rounds: Series A on May 4, 2022, Debt on Apr 14, 2020.
What is the total amount of funding VitroLabs has raised to date?
VitroLabs has raised a total of $53.1M in funding to date.
How many funding rounds has VitroLabs completed?
VitroLabs has completed 2 funding rounds.
How much funding did VitroLabs raise in its most recent funding round?
VitroLabs raised $53M in its most recent funding round.
Who are the lead investors in VitroLabs's latest funding round?
The lead investor in VitroLabs's latest funding round was FWD. To access investor data and explore similar companies, sign up for ZoomInfo.
Which was the largest funding round in VitroLabs's history?
The largest funding round in VitroLabs's history was $53M.
See more information about VitroLabs